Quarterly Result15 May 2025, 09:01 pm
Senores Pharmaceuticals Reports 91% Increase in Profit Before Tax for FY25
AI Summary
Senores Pharmaceuticals Limited, a global research-driven pharmaceutical company, announced its audited financial results for the 4th quarter of FY25. The company reported a 91% increase in Profit Before Tax (PBT) for FY25, with a significant growth in Regulated and Emerging Markets. The company also expanded its portfolio in the Regulated Markets and registered 48 new products across the Emerging Markets during Q4FY25.
Key Highlights
- Total Income and Profit before Tax for FY25 increased by 91% and 183% respectively on a year-on-year basis.
- Regulated Market Revenue stood at Rs. 244.8 crs, a growth of 69% on a Y-o-Y basis.
- Emerging Markets Revenue stood at Rs. 121.2 crs, a growth of 174% on a Y-o-Y basis.
- Registered 48 new products across the Emerging Markets during Q4FY25.
- Well placed to navigate uncertainties due to tariff situation in USA with USFDA-approved manufacturing facility in USA.